Boehringer Ingelheim and DxS into companion diagnostics
Ingelheim – Boehringer Ingelheim is to broaden its engagement in the field of companion diagnostics and has made an agreement with DxS from the UK for this purpose. The personalised Manchester-based medicine company will provide a companion diagnostic test kit for Boehringer Ingelheim's compound BIBW 2992 (Tovok^(TM)) to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non small cell lung cancer. As Boehringer said, clinical data suggest that BIBW 2992, a tyrosine kinase inhibitor that acts by irreversibly blocking the EGFR /HER2 receptors, offers a marked increase in efficacy in comparison to standard treatments, for lung cancer patients carrying mutations in the EGFR gene. Under the terms of the agreement, DxS and Boehringer Ingelheim will work jointly to make a suitable companion diagnostic test kit globally available, based on a real-time PCR assay, designed to detect the most common mutations in the EGFR gene. The kit has been developed and manufactured at DxS' UK head office and will be available later in the summer for Boehringer Ingelheim's global, multi-centre Phase III clinical trial for BIBW 2992. Financial terms of the agreement were not disclosed.